Also Maraviroc and BMS-813160: BMS-813160 overv
Post# of 148133
(Total Views: 760)
Posted On: 07/22/2024 11:16:23 PM
Re: HouseofCards #145257
Also Maraviroc and BMS-813160:
BMS-813160 overview:
BMS-813160 is under development for solid tumor, metastatic colorectal cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, gastric cancer, renal cell carcinoma and hepatocellular carcinoma. It is administered orally as a capsule. The drug candidate is a dual CCR2/CCR5 antagonist.
_______
So our trial results will eventually also be compared to Maraviroc & Bristol Meyers Squibb
Let's get it Leronlimab!!
BMS-813160 overview:
BMS-813160 is under development for solid tumor, metastatic colorectal cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, gastric cancer, renal cell carcinoma and hepatocellular carcinoma. It is administered orally as a capsule. The drug candidate is a dual CCR2/CCR5 antagonist.
_______
So our trial results will eventually also be compared to Maraviroc & Bristol Meyers Squibb
Let's get it Leronlimab!!
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼